Limited recovery from post-acute sequelae of SARS-CoV-2 at 8 months in a prospective cohort
- PMID: 34725634
- PMCID: PMC8504133
- DOI: 10.1183/23120541.00384-2021
Limited recovery from post-acute sequelae of SARS-CoV-2 at 8 months in a prospective cohort
Abstract
In a longitudinal cohort, a significant proportion of patients had persistent symptoms 8 months after initial #COVID19 infection. There was no significant improvement in symptoms or health-related quality of life between 4- and 8-month assessments. https://bit.ly/2Wtb7IX.
Copyright ©The authors 2021.
Conflict of interest statement
Conflict of interest: D.R. Darley has nothing to disclose. Conflict of interest: G.J. Dore reports grants from Gilead, Abbvie, Merck and Bristol-Myers Squibb, personal fees from Gilead, Abbvie and Merck, and nonfinancial support from Gilead, Abbvie and Merck, outside the submitted work. Conflict of interest: A.L. Byrne has nothing to disclose. Conflict of interest: M.L. Plit has nothing to disclose. Conflict of interest: B.J. Brew reports grants from St Vincent's Clinic during the conduct of the study; and personal fees from AbbVie, Janssen and Viiv, and grants from Biogen, outside the submitted work. Conflict of interest: A. Kelleher has nothing to disclose. Conflict of interest: G.V. Matthews has nothing to disclose.
Figures
References
LinkOut - more resources
Full Text Sources
Miscellaneous